CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | amino alcohol |
|
Accession: | CHEBI:22478
|
browse the term
|
Definition: | An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group. |
Synonyms: | related_synonym: | amino alcohols; aminoalcohol; aminoalcohols |
|
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding |
EXP |
Butaclamol binds to DRD2 protein |
CTD |
PMID:18457824 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
multiple interactions |
ISO |
Butaclamol inhibits the reaction [Dopamine results in increased activity of DRD3 protein] |
CTD |
PMID:31323226 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Drd4 |
dopamine receptor D4 |
affects binding |
EXP |
Butaclamol binds to Drd4 protein |
RGD |
PMID:8078498 |
RGD:7248459 |
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Butaclamol results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine] results in increased expression of APOA1 protein |
CTD |
PMID:16324916 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine] results in decreased expression of APOA2 protein |
CTD |
PMID:16324916 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine] results in decreased expression of APOB protein |
CTD |
PMID:16324916 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc1 |
apolipoprotein C1 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in increased expression of APOC1 protein |
CTD |
PMID:16324916 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC2 protein |
CTD |
PMID:16324916 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apoc3 |
apolipoprotein C3 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein |
CTD |
PMID:16324916 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[Caffeine co-treated with Ephedrine] results in increased cleavage of CASP3 protein |
CTD |
PMID:15537744 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD mRNA]; [Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD protein] |
CTD |
PMID:2307116 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Ephedrine results in increased expression of FOS mRNA |
CTD |
PMID:12730611 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
EXP |
[Caffeine co-treated with Ephedrine] results in increased phosphorylation of H2AX protein |
CTD |
PMID:15537744 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO |
Octopamine inhibits the reaction [Norepinephrine binds to ADRB1 protein] |
CTD |
PMID:10344530 |
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
Octopamine inhibits the reaction [Norepinephrine binds to ADRB2 protein] |
CTD |
PMID:10344530 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
increases activity multiple interactions |
EXP ISO |
Octopamine results in increased activity of ADRB3 protein Octopamine inhibits the reaction [Norepinephrine binds to ADRB3 protein] |
CTD |
PMID:10344530 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
ISO |
indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions |
ISO |
Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
multiple interactions increases activity |
ISO |
[Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 PMID:19725810 |
|
NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084
|
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
KRN 7000 results in increased expression of CXCL10 protein |
CTD |
PMID:15867097 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
KRN 7000 results in increased expression of IL12B protein |
CTD |
PMID:15867097 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
|
G |
Aamp |
angio-associated, migratory cell protein |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of AAMP protein |
CTD |
PMID:32044396 |
|
NCBI chr 9:75,863,382...75,869,188
Ensembl chr 9:75,863,389...75,868,547
|
|
G |
Aars1 |
alanyl-tRNA synthetase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of AARS protein |
CTD |
PMID:32044396 |
|
NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ABAT protein |
CTD |
PMID:32044396 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ACADM protein |
CTD |
PMID:32044396 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Adsl |
adenylosuccinate lyase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ADSL protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:112,479,256...112,503,439
Ensembl chr 7:112,479,271...112,503,760
|
|
G |
Akap1 |
A-kinase anchoring protein 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of AKAP1 protein |
CTD |
PMID:32044396 |
|
NCBI chr10:73,621,021...73,654,123
Ensembl chr10:73,621,883...73,653,896
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of AKR1C3 protein |
CTD |
PMID:32044396 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ALDH18A1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:239,375,657...239,407,967
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Anxa11 |
annexin A11 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ANXA11 protein |
CTD |
PMID:32044396 |
|
NCBI chr16:1,412,373...1,457,814
Ensembl chr16:1,410,756...1,457,797
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ANXA2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa6 |
annexin A6 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of ANXA6 protein |
CTD |
PMID:32044396 |
|
NCBI chr10:39,101,395...39,156,483
Ensembl chr10:39,097,109...39,156,433
|
|
G |
Arcn1 |
archain 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ARCN1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 8:45,057,617...45,082,224
Ensembl chr 8:45,057,619...45,082,247
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ARHGAP1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ATP6V1B2 protein |
CTD |
PMID:32044396 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Bag2 |
BAG cochaperone 2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of BAG2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721
|
|
G |
Cald1 |
caldesmon 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CALD1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 4:63,265,781...63,446,936
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Calm1 |
calmodulin 1 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of CALM1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CAMK2D protein |
CTD |
PMID:32044396 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CCT6A protein |
CTD |
PMID:32044396 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cd59 |
CD59 molecule |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CD59 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CDC42 protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cenpv |
centromere protein V |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CENPV protein |
CTD |
PMID:32044396 |
|
NCBI chr10:47,214,479...47,228,552
Ensembl chr10:47,214,490...47,228,761
|
|
G |
Cltc |
clathrin heavy chain |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CLTC protein |
CTD |
PMID:32044396 |
|
NCBI chr10:71,517,661...71,574,591
Ensembl chr10:71,517,663...71,573,737
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of COX4I1 protein |
CTD |
PMID:32044396 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Cpne1 |
copine 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CPNE1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:144,587,548...144,629,603
Ensembl chr 3:144,588,995...144,598,636
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of CPT1A protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Ctnnbl1 |
catenin, beta like 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CTNNBL1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:146,387,940...146,548,987
Ensembl chr 3:146,387,889...146,548,987
|
|
G |
Dctn1 |
dynactin subunit 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of DCTN1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 4:115,671,024...115,703,824
Ensembl chr 4:115,661,638...115,703,815
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of DCXR protein |
CTD |
PMID:32044396 |
|
NCBI chr10:106,006,404...106,008,294
|
|
G |
Ddx1 |
DEAD-box helicase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of DDX1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 6:35,996,469...36,027,340
Ensembl chr 6:35,996,469...36,027,365
|
|
G |
Ddx39b |
DExD-box helicase 39B |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of DDX39B protein |
CTD |
PMID:32044396 |
|
NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996
|
|
G |
Dynll1 |
dynein light chain LC8-type 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of DYNLL1 protein |
CTD |
PMID:32044396 |
|
NCBI chr12:41,312,367...41,314,742
Ensembl chr12:41,312,367...41,314,741
|
|
G |
Ebna1bp2 |
EBNA1 binding protein 2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of EBNA1BP2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:132,148,164...132,152,730
Ensembl chr 5:132,148,143...132,153,267
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of EEF1A1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Efhd2 |
EF-hand domain family, member D2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of EFHD2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980
|
|
G |
Ehd1 |
EH-domain containing 1 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of EHD1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of EIF2S3 protein |
CTD |
PMID:32044396 |
|
NCBI chr X:58,916,513...58,939,923
Ensembl chr X:58,917,490...58,940,686
|
|
G |
Eif3k |
eukaryotic translation initiation factor 3, subunit K |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of EIF3K protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:84,260,125...84,270,051
Ensembl chr 1:84,259,673...84,270,302
|
|
G |
Eps8l2 |
EPS8-like 2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of EPS8L2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:196,446,067...196,471,542
Ensembl chr 1:196,446,287...196,471,541
|
|
G |
Esyt1 |
extended synaptotagmin 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of ESYT1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:928,848...946,199
Ensembl chr 7:928,848...946,199
|
|
G |
Farsa |
phenylalanyl-tRNA synthetase subunit alpha |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of FARSA protein |
CTD |
PMID:32044396 |
|
NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980
|
|
G |
Fdps |
farnesyl diphosphate synthase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of FDPS protein |
CTD |
PMID:32044396 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fga |
fibrinogen alpha chain |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of FGA protein |
CTD |
PMID:32044396 |
|
NCBI chr 2:168,365,364...168,381,533
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of GPT2 protein |
CTD |
PMID:32044396 |
|
NCBI chr19:21,526,800...21,561,314
Ensembl chr19:21,517,621...21,560,610
|
|
G |
Grhpr |
glyoxylate and hydroxypyruvate reductase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of GRHPR protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:59,234,179...59,243,614
Ensembl chr 5:59,234,192...59,243,603
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of HADHA protein |
CTD |
PMID:32044396 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hgd |
homogentisate 1, 2-dioxygenase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of HGD protein |
CTD |
PMID:32044396 |
|
NCBI chr11:63,086,750...63,138,325
Ensembl chr11:63,086,752...63,138,323
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of HNRNPA2B1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 4:80,534,659...80,545,297
Ensembl chr 4:80,534,651...80,545,249
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of HNRNPD protein |
CTD |
PMID:32044396 |
|
NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of HNRNPH2 protein |
CTD |
PMID:32044396 |
|
NCBI chr X:97,780,890...97,786,846
Ensembl chr X:97,780,785...97,787,041
|
|
G |
Hnrnpr |
heterogeneous nuclear ribonucleoprotein R |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of HNRNPR protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:148,542,999...148,574,888
Ensembl chr 5:148,543,044...148,574,867
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of HSPA1A protein |
CTD |
PMID:32044396 |
|
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of HSPB1 protein |
CTD |
PMID:32044396 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Iars2 |
isoleucyl-tRNA synthetase 2, mitochondrial |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of IARS2 protein |
CTD |
PMID:32044396 |
|
NCBI chr13:96,831,773...96,865,533
Ensembl chr13:96,831,484...96,865,501
|
|
G |
Immt |
inner membrane mitochondrial protein |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of IMMT protein |
CTD |
PMID:32044396 |
|
NCBI chr 4:103,880,482...103,919,116
Ensembl chr 4:103,880,459...103,919,109
|
|
G |
Ipo4 |
importin 4 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of IPO4 protein |
CTD |
PMID:32044396 |
|
NCBI chr15:29,117,365...29,127,382
Ensembl chr15:29,117,365...29,127,285
|
|
G |
Ipo5 |
importin 5 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of IPO5 protein |
CTD |
PMID:32044396 |
|
NCBI chr15:97,990,755...98,041,074
Ensembl chr15:98,005,299...98,041,126
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of IQGAP1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
|
|
G |
Khsrp |
KH-type splicing regulatory protein |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of KHSRP protein |
CTD |
PMID:32044396 |
|
NCBI chr 9:1,862,555...1,872,301
Ensembl chr 9:1,862,899...1,872,451
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of KRT19 protein |
CTD |
PMID:32044396 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Lamtor1 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of LAMTOR1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:156,272,116...156,277,687
Ensembl chr 1:156,272,064...156,291,179
|
|
G |
LOC102556347 |
carbonyl reductase [NADPH] 1-like |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of CBR1 protein |
CTD |
PMID:32044396 |
|
NCBI chr11:32,892,640...32,895,277
Ensembl chr11:32,857,991...32,895,275
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of MAP1LC3B protein modified form |
CTD |
PMID:32044396 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of MAPK1 protein |
CTD |
PMID:32044396 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mif |
macrophage migration inhibitory factor |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of MIF protein |
CTD |
PMID:32044396 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mtch2 |
mitochondrial carrier 2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of MTCH2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:76,830,549...76,850,189
Ensembl chr 3:76,830,413...76,850,189
|
|
G |
Mvp |
major vault protein |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of MVP protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:181,594,734...181,622,336
Ensembl chr 1:181,594,734...181,622,380
|
|
G |
Nap1l1 |
nucleosome assembly protein 1-like 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of NAP1L1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:46,933,278...46,957,853
Ensembl chr 7:46,933,356...46,956,593
|
|
G |
Nars1 |
asparaginyl-tRNA synthetase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of NARS protein |
CTD |
PMID:32044396 |
|
NCBI chr18:57,989,308...58,005,639
Ensembl chr18:57,989,308...58,005,622
|
|
G |
Nasp |
nuclear autoantigenic sperm protein |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of NASP protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:130,057,363...130,083,003
Ensembl chr 5:130,057,363...130,082,928
|
|
G |
Neu1 |
neuraminidase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of NEU1 protein |
CTD |
PMID:32044396 |
|
NCBI chr20:3,897,480...3,901,745
Ensembl chr20:3,897,480...3,901,745
|
|
G |
Nifk |
nucleolar protein interacting with the FHA domain of MKI67 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of NIFK protein |
CTD |
PMID:32044396 |
|
NCBI chr13:29,393,303...29,403,387
Ensembl chr13:29,393,286...29,405,896
|
|
G |
P3h1 |
prolyl 3-hydroxylase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of P3H1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:132,841,868...132,856,664
Ensembl chr 5:132,841,928...132,856,659
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of PA2G4 protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Pak2 |
p21 (RAC1) activated kinase 2 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of PAK2 protein |
CTD |
PMID:32044396 |
|
NCBI chr11:68,708,070...68,766,622
Ensembl chr11:68,707,969...68,768,816
|
|
G |
Park7 |
Parkinsonism associated deglycase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PARK7 protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PARP1 protein |
CTD |
PMID:32044396 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pc |
pyruvate carboxylase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PC protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pdhb |
pyruvate dehydrogenase E1 subunit beta |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PDHB protein |
CTD |
PMID:32044396 |
|
NCBI chr15:16,752,561...16,758,503
Ensembl chr15:16,750,980...16,758,500
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PHGDH protein |
CTD |
PMID:32044396 |
|
NCBI chr 2:185,906,964...185,936,160
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Pnn |
pinin, desmosome associated protein |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PNN protein |
CTD |
PMID:32044396 |
|
NCBI chr 6:76,758,138...76,766,451
Ensembl chr 6:76,758,117...76,766,889
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of PRDX1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:130,147,276...130,162,850
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prdx3 |
peroxiredoxin 3 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PRDX3 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111
|
|
G |
Psma5 |
proteasome 20S subunit alpha 5 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PSMA5 protein |
CTD |
PMID:32044396 |
|
NCBI chr 2:195,896,369...195,919,733
Ensembl chr 2:195,896,365...195,919,731
|
|
G |
Psmc2 |
proteasome 26S subunit, ATPase 2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PSMC2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 4:13,255,851...13,270,102
Ensembl chr 4:13,255,856...13,270,185
|
|
G |
Psmc3 |
proteasome 26S subunit, ATPase 3 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PSMC3 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:77,031,825...77,037,207
Ensembl chr 3:77,031,825...77,043,358
|
|
G |
Psmc4 |
proteasome 26S subunit, ATPase 4 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of PSMC4 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494
|
|
G |
Qars1 |
glutaminyl-tRNA synthetase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of QARS protein |
CTD |
PMID:32044396 |
|
NCBI chr 8:109,207,705...109,215,738
Ensembl chr 8:109,207,705...109,215,739
|
|
G |
Rab14 |
RAB14, member RAS oncogene family |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RAB14 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:18,501,953...18,523,253
Ensembl chr 3:18,501,963...18,523,172
|
|
G |
Rab5c |
RAB5C, member RAS oncogene family |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RAB5C protein |
CTD |
PMID:32044396 |
|
NCBI chr10:85,642,553...85,666,142
Ensembl chr10:85,642,809...85,666,103
|
|
G |
Ran |
RAN, member RAS oncogene family |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RAN protein |
CTD |
PMID:32044396 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rangap1 |
RAN GTPase activating protein 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RANGAP1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:113,224,695...113,250,441
Ensembl chr 7:113,224,703...113,250,438
|
|
G |
Rbbp7 |
RB binding protein 7, chromatin remodeling factor |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RBBP7 protein |
CTD |
PMID:32044396 |
|
NCBI chr X:31,913,080...31,931,245
Ensembl chr X:31,913,081...31,931,226
|
|
G |
Rbm8a |
RNA binding motif protein 8A |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RBM8A protein |
CTD |
PMID:32044396 |
|
NCBI chr 2:184,165,189...184,167,959
Ensembl chr 2:184,165,193...184,167,959
|
|
G |
Rcc1 |
regulator of chromosome condensation 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RCC1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:144,526,025...144,544,445
Ensembl chr 5:144,526,025...144,544,577
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RHOA protein |
CTD |
PMID:32044396 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rpl18 |
ribosomal protein L18 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RPL18 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:96,188,811...96,191,452
Ensembl chr 1:96,188,112...96,191,452
|
|
G |
Rpl22 |
ribosomal protein L22 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RPL22 protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:162,835,251...162,841,977
Ensembl chr 5:162,833,740...162,843,368
|
|
G |
Rpl23 |
ribosomal protein L23 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RPL23 protein |
CTD |
PMID:32044396 |
|
NCBI chr10:82,771,878...82,775,840
Ensembl chr10:82,771,538...82,775,870
|
|
G |
Rpl24 |
ribosomal protein L24 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RPL24 protein |
CTD |
PMID:32044396 |
|
NCBI chr11:44,653,937...44,659,346
Ensembl chr11:44,653,937...44,659,370
|
|
G |
Rpl3 |
ribosomal protein L3 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of RPL3 protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:111,622,257...111,627,639
Ensembl chr 7:111,621,610...111,636,468
|
|
G |
Rpl30 |
ribosomal protein L30 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RPL30 protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:65,648,470...65,651,363
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363
|
|
G |
Rpn2 |
ribophorin II |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RPN2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:145,941,787...145,989,271
Ensembl chr 3:145,941,839...145,989,543
|
|
G |
Rps16 |
ribosomal protein S16 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RPS16 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:83,643,066...83,646,056
Ensembl chr 1:83,643,130...83,646,206
|
|
G |
Rps20 |
ribosomal protein S20 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RPS20 protein |
CTD |
PMID:32044396 |
|
NCBI chr 5:16,819,313...16,820,475
Ensembl chr 5:16,819,304...16,820,475
|
|
G |
Rps5 |
ribosomal protein S5 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RPS5 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:73,538,776...73,543,073
Ensembl chr 1:73,538,776...73,543,073
|
|
G |
Rtn4 |
reticulon 4 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of RTN4 protein |
CTD |
PMID:32044396 |
|
NCBI chr14:103,450,074...103,497,687
Ensembl chr14:103,449,930...103,497,686
|
|
G |
Sec23a |
Sec23 homolog A, COPII coat complex component |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of SEC23A protein |
CTD |
PMID:32044396 |
|
NCBI chr 6:76,658,793...76,706,125
Ensembl chr 6:76,658,427...76,706,035
|
|
G |
Serpinh1 |
serpin family H member 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of SERPINH1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Son |
SON DNA and RNA binding protein |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of SON protein |
CTD |
PMID:32044396 |
|
NCBI chr11:30,850,890...30,923,167
Ensembl chr11:30,892,005...30,923,167
|
|
G |
Srp14 |
signal recognition particle 14 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of SRP14 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:105,442,184...105,445,875
Ensembl chr 3:105,442,198...105,445,859
|
|
G |
Srsf7 |
serine and arginine rich splicing factor 7 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of SRSF7 protein |
CTD |
PMID:32044396 |
|
NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965
|
|
G |
Ssb |
small RNA binding exonuclease protection factor La |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of SSB protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:54,616,616...54,626,203
Ensembl chr 3:54,616,619...54,626,203
|
|
G |
Ssr4 |
signal sequence receptor subunit 4 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of SSR4 protein |
CTD |
PMID:32044396 |
|
NCBI chr X:151,524,191...151,528,218
Ensembl chr X:151,524,009...151,528,202
|
|
G |
Sugt1 |
SGT1 homolog, MIS12 kinetochore complex assembly cochaperone |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of SUGT1 protein |
CTD |
PMID:32044396 |
|
NCBI chr15:54,991,419...55,032,244
Ensembl chr15:54,990,672...55,069,150
|
|
G |
Syncrip |
synaptotagmin binding, cytoplasmic RNA interacting protein |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of SYNCRIP protein |
CTD |
PMID:32044396 |
|
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
|
|
G |
Tars1 |
threonyl-tRNA synthetase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of TARS protein |
CTD |
PMID:32044396 |
|
NCBI chr 2:60,368,251...60,387,733
Ensembl chr 2:60,367,796...60,387,717
|
|
G |
Tjp2 |
tight junction protein 2 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of TJP2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:221,709,745...221,838,383
Ensembl chr 1:221,709,745...221,838,295
|
|
G |
Tpd52l2 |
TPD52 like 2 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of TPD52L2 protein |
CTD |
PMID:32044396 |
|
NCBI chr 3:168,598,449...168,618,201
Ensembl chr 3:168,594,609...168,619,762
|
|
G |
Trap1 |
TNF receptor-associated protein 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of TRAP1 protein |
CTD |
PMID:32044396 |
|
NCBI chr10:11,464,882...11,498,931
Ensembl chr10:11,464,821...11,498,981
|
|
G |
Trim28 |
tripartite motif-containing 28 |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of TRIM28 protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:73,652,441...73,659,388
Ensembl chr 1:73,652,709...73,659,380
|
|
G |
Tst |
thiosulfate sulfurtransferase |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of TST protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:109,948,061...109,955,378
Ensembl chr 7:109,948,062...109,957,216
|
|
G |
Tuba1c |
tubulin, alpha 1C |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of TUBA1C protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:130,192,050...130,199,655
Ensembl chr 7:130,192,016...130,199,647
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of TUBB2B protein |
CTD |
PMID:32044396 |
|
NCBI chr17:30,747,734...30,750,781
Ensembl chr17:30,747,734...30,750,638
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of TUFM protein |
CTD |
PMID:32044396 |
|
NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395
|
|
G |
Twf1 |
twinfilin actin-binding protein 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of TWF1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:125,715,938...125,727,834
Ensembl chr 7:125,716,015...125,727,894
|
|
G |
Ube2n |
ubiquitin-conjugating enzyme E2N |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of UBE2N protein |
CTD |
PMID:32044396 |
|
NCBI chr 7:30,154,330...30,184,373
Ensembl chr 7:30,154,616...30,184,355
|
|
G |
Uggt1 |
UDP-glucose glycoprotein glucosyltransferase 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of UGGT1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 9:38,355,229...38,468,473
Ensembl chr 9:38,359,089...38,468,467
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of UQCRC1 protein |
CTD |
PMID:32044396 |
|
NCBI chr 8:109,589,735...109,601,481
Ensembl chr 8:109,589,706...109,601,480
|
|
G |
Xpo5 |
exportin 5 |
decreases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in decreased expression of XPO5 protein |
CTD |
PMID:32044396 |
|
NCBI chr 9:14,740,182...14,778,171
Ensembl chr 9:14,740,182...14,778,171
|
|
G |
Zyx |
zyxin |
increases expression |
ISO |
2-amino-14,16-dimethyloctadecan-3-ol results in increased expression of ZYX protein |
CTD |
PMID:32044396 |
|
NCBI chr 4:71,236,767...71,246,553
Ensembl chr 4:71,237,451...71,246,553
|
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions increases response to substance |
ISO |
9-((2-phosphonylmethoxy)ethyl)guanine analog inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine]; Quercetin inhibits the reaction [SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine analog] SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine; SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine analog |
CTD |
PMID:23856525 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions increases activity |
ISO |
[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Acebutolol results in increased activity of ADRB1 protein] |
CTD |
PMID:12761341 |
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Acebutolol results in increased expression of FOS mRNA |
CTD |
PMID:12730611 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:17925438 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17925438 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Ren |
renin |
decreases activity |
ISO EXP |
Acebutolol results in decreased activity of REN protein |
CTD |
PMID:6110712 PMID:6118215 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
acetophenazine binds to and results in decreased activity of AR protein |
CTD |
PMID:17606915 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO EXP |
Albuterol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Albuterol inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein] |
CTD |
PMID:8096834 PMID:14730417 |
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases response to substance increases activity multiple interactions increases phosphorylation decreases expression |
ISO EXP |
ADRB2 gene polymorphism results in decreased susceptibility to Albuterol Albuterol results in increased activity of ADRB2 protein [Albuterol binds to and results in increased activity of ADRB2 protein] which results in decreased abundance of Potassium; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Albuterol binds to and results in increased activity of ADRB2 protein; Albuterol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Albuterol results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein] Albuterol results in increased phosphorylation of ADRB2 protein Albuterol results in decreased expression of ADRB2 protein [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Hydroxyindoleacetic Acid; Albuterol binds to and results in increased activity of ADRB2 protein |
CTD |
PMID:2463453 PMID:8102213 PMID:8937731 PMID:10516654 PMID:10952688 PMID:12920204 PMID:14722251 PMID:14730417 PMID:15467267 PMID:15687340 PMID:16980553 PMID:19120125 PMID:19363516 PMID:34601065 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
[Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Albuterol binds to and results in increased activity of ADRB3 protein; Albuterol inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Albuterol results in increased expression of BAX |
CTD |
PMID:11802967 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Albuterol results in decreased expression of BCL2 |
CTD |
PMID:11802967 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol] |
CTD |
PMID:19462961 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein] |
CTD |
PMID:12818968 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Albuterol] results in decreased secretion of CCL5 protein |
CTD |
PMID:15679717 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]] |
CTD |
PMID:18076728 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
increases expression |
ISO |
Albuterol results in increased expression of CDK2 protein |
CTD |
PMID:18362475 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
ISO |
Albuterol results in increased expression of CDK4 protein |
CTD |
PMID:18362475 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Ckm |
creatine kinase, M-type |
increases secretion |
ISO |
Albuterol results in increased secretion of CKM protein |
CTD |
PMID:8970440 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Albuterol] results in decreased secretion of CSF2 protein |
CTD |
PMID:15679717 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
Albuterol results in increased expression of CYP17A1 |
CTD |
PMID:17822730 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Cyproterone co-treated with Albuterol] results in decreased expression of CYP19A1 |
CTD |
PMID:17822730 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Albuterol promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein] |
CTD |
PMID:18076728 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein] |
CTD |
PMID:18076728 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases activity |
EXP |
Albuterol results in increased activity of G6PD protein |
CTD |
PMID:1978808 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
EXP |
Albuterol results in decreased expression of IL10 mRNA |
CTD |
PMID:16908771 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Albuterol results in decreased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO |
Albuterol promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] Albuterol results in decreased expression of IL1B mRNA |
CTD |
PMID:11112151 PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Albuterol results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]] |
CTD |
PMID:18076728 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
1-Methyl-3-isobutylxanthine promotes the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]]; Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]; ICI 118551 inhibits the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]] |
CTD |
PMID:16238794 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
Albuterol results in increased expression of IL6 protein Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] [Albuterol co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; [Dexamethasone co-treated with Albuterol] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; [Theophylline co-treated with Albuterol] inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Albuterol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Albuterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:18362475 PMID:20388727 PMID:20519841 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
increases expression |
ISO |
Albuterol results in increased expression of INS; Albuterol results in increased expression of INS protein |
CTD |
PMID:8098220 PMID:9088585 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Ldlr |
low density lipoprotein receptor |
affects response to substance |
ISO |
LDLR gene SNP affects the susceptibility to Albuterol |
CTD |
PMID:15453913 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein Albuterol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:16980553 PMID:20519841 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein Albuterol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:16980553 PMID:20519841 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol; Ascorbic Acid inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; CAT protein inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Glutathione inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Sodium Azide inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Sodium Cyanide inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol] |
CTD |
PMID:19462961 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression |
ISO |
Albuterol results in increased expression of NFKBIA protein |
CTD |
PMID:18362475 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:20519841 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Albuterol] affects the localization of NR3C1 protein |
CTD |
PMID:15679717 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Pde4a |
phosphodiesterase 4A |
multiple interactions |
ISO |
[Albuterol co-treated with Rolipram] results in increased expression of PDE4A mRNA |
CTD |
PMID:10763856 |
|
NCBI chr 8:19,706,649...19,751,937
Ensembl chr 8:19,703,290...19,751,961
|
|
G |
Pde4b |
phosphodiesterase 4B |
multiple interactions |
ISO |
[Albuterol co-treated with Rolipram] results in increased expression of PDE4B mRNA |
CTD |
PMID:10763856 |
|
NCBI chr 5:116,799,827...117,367,707
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Albuterol results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
Albuterol results in decreased activity of PON1 protein |
CTD |
PMID:31581362 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Albuterol results in increased expression of PPARGC1A mRNA |
CTD |
PMID:17446185 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptafr |
platelet-activating factor receptor |
increases expression |
ISO |
Albuterol results in increased expression of PTAFR protein |
CTD |
PMID:18362475 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression |
ISO |
Albuterol promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] Albuterol results in decreased expression of PTGS2 mRNA |
CTD |
PMID:11112151 PMID:32816093 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression multiple interactions increases expression |
ISO |
Albuterol results in decreased expression of RB1 protein ICI 118551 inhibits the reaction [Albuterol results in decreased expression of RB1 protein] Albuterol results in increased expression of RB1 protein |
CTD |
PMID:16446544 PMID:18362475 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Ren |
renin |
increases expression |
ISO |
Albuterol results in increased expression of REN protein |
CTD |
PMID:2829953 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
decreases expression |
ISO |
Albuterol results in decreased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
ISO |
Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]] |
CTD |
PMID:18076728 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions |
ISO EXP |
Albuterol results in decreased secretion of TNF protein [Albuterol co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; [Dexamethasone co-treated with Albuterol] inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Albuterol promotes the reaction [Theophylline inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]] |
CTD |
PMID:8937731 PMID:10229875 PMID:20388727 PMID:20519841 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Albuterol results in increased expression of TP53 |
CTD |
PMID:11802967 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression |
ISO |
Albuterol results in increased expression of UCP1 protein |
CTD |
PMID:10465291 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ucp3 |
uncoupling protein 3 |
multiple interactions |
ISO |
[Albuterol co-treated with acipimox] results in decreased expression of UCP3 mRNA |
CTD |
PMID:12824081 |
|
NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of anandamide |
CTD |
PMID:30102254 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein |
CTD |
PMID:30610963 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance decreases metabolic processing decreases abundance |
EXP ISO |
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide |
CTD |
PMID:22233683 PMID:26976670 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions decreases activity |
ISO |
AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] |
CTD |
PMID:19022239 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:26513129 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein |
CTD |
PMID:17360047 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
ISO |
anandamide results in decreased expression of CGA mRNA |
CTD |
PMID:30610963 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects activity increases response to substance decreases expression affects binding increases activity multiple interactions |
ISO EXP |
anandamide affects the activity of CNR1 protein CNR1 protein results in increased susceptibility to anandamide anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] |
CTD |
PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 PMID:15453094 PMID:17557913 PMID:19147270 PMID:29730318 PMID:31024316 PMID:31199905 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects activity multiple interactions affects binding |
ISO EXP |
anandamide affects the activity of CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide] anandamide binds to CNR2 protein |
CTD |
PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:30610963 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
decreases abundance |
ISO |
CRH protein results in decreased abundance of anandamide |
CTD |
PMID:26821211 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions increases metabolic processing |
ISO |
cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide] |
CTD |
PMID:29689453 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein] |
CTD |
PMID:21949157 PMID:26513129 PMID:29441458 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO |
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:26513129 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
decreases expression |
ISO |
anandamide results in decreased expression of ERVFRD-1 mRNA |
CTD |
PMID:30610963 |
|
NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] anandamide results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Faah |
fatty acid amide hydrolase |
increases degradation increases response to substance decreases metabolic processing multiple interactions affects expression |
ISO EXP |
FAAH results in increased degradation of anandamide FAAH gene mutant form results in increased susceptibility to anandamide FAAH gene mutant form results in decreased metabolism of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide] |
CTD |
PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 PMID:23761300 PMID:26642910 PMID:27307500 PMID:27385208 PMID:29787777 PMID:31121907 More...
|
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions affects abundance affects binding |
EXP ISO |
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] FABP1 protein affects the abundance of anandamide FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 PMID:30232874 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein |
CTD |
PMID:9748483 PMID:15601931 PMID:19515121 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B] |
CTD |
PMID:12813001 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
anandamide results in increased expression of IGF1 protein |
CTD |
PMID:17307377 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:15748152 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] |
CTD |
PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:30611738 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lep |
leptin |
decreases abundance multiple interactions decreases activity decreases transport |
ISO |
LEP protein results in decreased abundance of anandamide Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide] LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide |
CTD |
PMID:16154199 PMID:29967158 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
anandamide results in increased expression of MMP1 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
anandamide results in increased expression of MMP3 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:11891798 PMID:15748152 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
anandamide results in increased cleavage of PARP1 protein |
CTD |
PMID:29441458 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
anandamide binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression increases metabolic processing |
EXP ISO |
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide] |
CTD |
PMID:16330497 PMID:17245358 PMID:20702753 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein] anandamide results in increased expression of SELP protein |
CTD |
PMID:27151562 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance |
EXP ISO |
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF] |
CTD |
PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases response to substance increases activity affects response to substance affects binding |
ISO EXP |
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein anandamide binds to TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] |
CTD |
PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 PMID:15615864 PMID:17038422 PMID:17913835 PMID:18550765 PMID:21949157 More...
|
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
anandamide results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:15313899 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
asperphenamate analog binds to and results in decreased activity of CTSL protein |
CTD |
PMID:30253340 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctss |
cathepsin S |
multiple interactions |
ISO |
asperphenamate analog binds to and results in decreased activity of CTSS protein |
CTD |
PMID:30253340 |
|
NCBI chr 2:183,089,192...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Atenolol results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
affects response to substance |
ISO |
ADRA2A gene SNP affects the susceptibility to Atenolol |
CTD |
PMID:15614026 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases activity multiple interactions affects binding affects response to substance decreases expression |
ISO EXP |
Atenolol results in decreased activity of ADRB1 protein Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] Atenolol binds to ADRB1 protein [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased susceptibility to Nicotine; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein] ADRB1 protein polymorphism affects the susceptibility to Atenolol Atenolol results in decreased expression of ADRB1 mRNA |
CTD |
PMID:1389726 PMID:2462161 PMID:2897299 PMID:8102213 PMID:8386603 PMID:9593075 PMID:10372227 PMID:10894789 PMID:11425575 PMID:11483288 PMID:12022239 PMID:12761341 PMID:14730417 PMID:15060759 PMID:17003101 PMID:17369603 PMID:17628611 PMID:22192668 More...
|
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases expression affects binding multiple interactions |
ISO EXP |
Atenolol results in increased expression of ADRB2 protein Atenolol binds to ADRB2 protein Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein] [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Atenolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein] |
CTD |
PMID:2462161 PMID:6093157 PMID:9593075 PMID:11425575 PMID:11483288 PMID:12920204 PMID:14730417 PMID:17925438 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Agt |
angiotensinogen |
affects response to substance decreases expression |
ISO |
AGT gene SNP affects the susceptibility to Atenolol Atenolol results in decreased expression of AGT protein |
CTD |
PMID:14639093 PMID:14700505 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Amy1 |
amylase alpha 1 |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Cisplatin results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Isoproterenol results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Lithium Chloride results in increased secretion of and results in increased activity of AMY1A protein] |
CTD |
PMID:21173550 |
|
NCBI chr 2:201,382,678...201,397,487
Ensembl chr 2:201,382,675...201,397,816
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
ISO |
Atenolol results in decreased expression of APOA1 protein |
CTD |
PMID:2193493 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
decreases expression |
ISO |
Atenolol results in decreased expression of APOA2 protein |
CTD |
PMID:2193493 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apob |
apolipoprotein B |
increases expression |
ISO |
Atenolol results in increased expression of APOB; Atenolol results in increased expression of APOB protein |
CTD |
PMID:1928808 PMID:2193493 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:16671086 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
B2m |
beta-2 microglobulin |
decreases expression |
ISO |
Atenolol results in decreased expression of B2M protein |
CTD |
PMID:2656332 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects response to substance |
ISO |
BDKRB2 exon polymorphism affects the susceptibility to Atenolol |
CTD |
PMID:12640257 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
increases response to substance |
ISO |
CACNA1C gene polymorphism results in increased susceptibility to Atenolol |
CTD |
PMID:20031608 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein] |
CTD |
PMID:10728402 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]; Atenolol promotes the reaction [Quercetin inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]]; Atenolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Quercetin promotes the reaction [Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]] |
CTD |
PMID:2575990 PMID:22391854 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Isoproterenol results in increased expression of CDK1 mRNA] |
CTD |
PMID:9593584 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:16671086 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Edn1 |
endothelin 1 |
affects response to substance |
ISO |
EDN1 gene polymorphism affects the susceptibility to Atenolol |
CTD |
PMID:15188945 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein] |
CTD |
PMID:16671086 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Epinephrine results in increased expression of FAS protein] |
CTD |
PMID:10728402 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Epinephrine results in increased expression of FASLG protein] |
CTD |
PMID:10728402 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
Atenolol promotes the reaction [FKBP1B protein binds to RYR2 protein] |
CTD |
PMID:12743001 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
decreases expression |
ISO |
Atenolol results in decreased expression of FKBP5 mRNA |
CTD |
PMID:19915711 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Dopamine results in increased activity of G6PD protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of G6PD protein] |
CTD |
PMID:1978808 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
EXP |
Atenolol results in increased expression of GJA1 protein |
CTD |
PMID:16448880 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja4 |
gap junction protein, alpha 4 |
increases expression |
EXP |
Atenolol results in increased expression of GJA4 protein |
CTD |
PMID:16448880 |
|
NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
decreases expression |
ISO |
Atenolol results in decreased expression of GRK2 mRNA; Atenolol results in decreased expression of GRK2 protein |
CTD |
PMID:9788834 |
|
NCBI chr 1:201,581,480...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Terbutaline results in increased expression of INS protein] |
CTD |
PMID:12795776 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
affects response to substance |
ISO |
KCNJ2 gene affects the susceptibility to Atenolol |
CTD |
PMID:15028050 |
|
NCBI chr10:96,060,849...96,071,401
Ensembl chr10:96,060,821...96,071,445
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
affects response to substance |
ISO |
KCNQ1 gene affects the susceptibility to Atenolol |
CTD |
PMID:15028050 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
LIPC gene SNP affects the susceptibility to and affects the metabolism of Atenolol |
CTD |
PMID:23536766 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
LOC120096121 |
small nucleolar RNA SNORA49 |
increases expression |
ISO |
Atenolol results in increased expression of SNORA49 mRNA |
CTD |
PMID:19915711 |
|
NCBI chr12:45,970,884...45,971,016
Ensembl chr12:45,970,884...45,971,016
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16671086 PMID:17003101 PMID:17925438 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16671086 PMID:17003101 PMID:17925438 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] |
CTD |
PMID:19439816 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
ISO |
Atenolol results in decreased expression of NPPA protein |
CTD |
PMID:12866806 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions decreases expression increases expression |
EXP ISO |
[Atenolol co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA Atenolol results in decreased expression of NPPB mRNA Atenolol results in increased expression of NPPB protein |
CTD |
PMID:15969258 PMID:18192850 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Pla2g4c |
phospholipase A2 group IVC |
multiple interactions |
ISO |
PLA2G4C gene SNP affects the susceptibility to and affects the metabolism of Atenolol |
CTD |
PMID:23536766 |
|
NCBI chr 1:74,249,688...74,272,133
Ensembl chr 1:74,236,211...74,274,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein] |
CTD |
PMID:17003101 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn5 |
protein tyrosine phosphatase, non-receptor type 5 |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] |
CTD |
PMID:17623046 |
|
NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882
|
|
G |
Ren |
renin |
multiple interactions decreases expression decreases activity |
ISO EXP |
[aliskiren co-treated with Atenolol] results in decreased activity of REN protein; [Dexamethasone co-treated with Nifedipine co-treated with Atenolol co-treated with Antihypertensive Agents] results in increased secretion of REN protein Atenolol results in decreased expression of REN protein Atenolol inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of REN protein]; Atenolol inhibits the reaction [2-hexynyladenosine-5'-N-ethylcarboxamide results in increased expression of REN protein] Atenolol results in decreased activity of REN protein |
CTD |
PMID:3142437 PMID:3333524 PMID:9300315 PMID:14639093 PMID:18957387 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Ryr2 |
ryanodine receptor 2 |
increases activity multiple interactions |
ISO |
Atenolol results in increased activity of RYR2 protein Atenolol promotes the reaction [FKBP1B protein binds to RYR2 protein] |
CTD |
PMID:12743001 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
Slc19a1 |
solute carrier family 19 member 1 |
decreases expression |
ISO |
Atenolol results in decreased expression of SLC19A1 mRNA |
CTD |
PMID:19616087 |
|
NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc6a8 |
solute carrier family 6 member 8 |
decreases expression |
ISO |
Atenolol results in decreased expression of SLC6A8 mRNA |
CTD |
PMID:19915711 |
|
NCBI chr X:151,384,675...151,393,979
Ensembl chr X:151,384,675...151,393,979
|
|
G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
increases expression |
ISO |
Atenolol results in increased expression of SLCO4C1 mRNA |
CTD |
PMID:19915711 |
|
NCBI chr 9:97,180,162...97,229,135
Ensembl chr 9:97,178,861...97,229,715
|
|
G |
Snrpn |
small nuclear ribonucleoprotein polypeptide N |
increases expression |
ISO |
Atenolol results in increased expression of SNRPN mRNA |
CTD |
PMID:19915711 |
|
NCBI chr 1:111,101,327...111,123,400
Ensembl chr 1:111,101,329...111,123,634
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO EXP |
Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD1 protein] Atenolol promotes the reaction [Thyroxine results in decreased expression of SOD1 protein] |
CTD |
PMID:2575990 PMID:11163531 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO EXP |
Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD2 protein] Atenolol inhibits the reaction [Thyroxine results in increased expression of SOD2 protein] |
CTD |
PMID:2575990 PMID:11163531 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
decreases response to substance |
ISO |
TRPA1 gene mutant form results in decreased susceptibility to Atenolol |
CTD |
PMID:29627347 |
|
NCBI chr 5:4,379,999...4,433,243
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
Atenolol results in increased expression of TXN mRNA |
CTD |
PMID:19915711 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
bambuterol results in decreased activity of ACHE protein |
CTD |
PMID:18582854 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases activity |
ISO |
bambuterol results in increased activity of ADRB2 protein |
CTD |
PMID:34601065 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity |
ISO |
bambuterol results in decreased activity of BCHE protein |
CTD |
PMID:15652380 PMID:18582854 PMID:18977317 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions affects binding |
EXP ISO |
Betaxolol affects the reaction [Cocaine affects the expression of ADRB1 protein]; Betaxolol inhibits the reaction [Cocaine affects the expression of ADRB1 protein] Betaxolol binds to ADRB1 protein Betaxolol binds to and results in decreased activity of ADRB1 protein |
CTD |
PMID:10372227 PMID:11436944 PMID:17513029 PMID:18596687 |
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Betaxolol binds to and results in decreased activity of ADRB2 protein |
CTD |
PMID:11436944 PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Betaxolol affects the reaction [Cocaine affects the phosphorylation of CREB1 protein] |
CTD |
PMID:18596687 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
Betaxolol affects the reaction [Cocaine affects the expression of CRH mRNA] |
CTD |
PMID:18596687 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
EXP |
Betaxolol results in decreased expression of NPPA mRNA; Betaxolol results in decreased expression of NPPA protein |
CTD |
PMID:12693380 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
EXP |
Betaxolol results in decreased expression of NPPB mRNA |
CTD |
PMID:12693380 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases expression |
EXP |
bevantolol results in decreased expression of ADRB1 mRNA |
CTD |
PMID:17628611 |
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases activity |
ISO |
ICI 118551 inhibits the reaction [bitolterol results in increased activity of ADRB2 protein] |
CTD |
PMID:34601065 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
Cytidine Diphosphate Choline results in decreased expression of CASP3 protein |
CTD |
PMID:12443983 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
EXP |
Cytidine Diphosphate Choline results in decreased expression of ICAM1 mRNA |
CTD |
PMID:16193989 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression |
ISO |
Cytidine Diphosphate Choline results in decreased expression of PARP1 protein modified form |
CTD |
PMID:12443983 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression multiple interactions |
EXP |
Cytidine Diphosphate Choline results in increased expression of SIRT1 protein Cytidine Diphosphate Choline results in increased expression of and results in increased activity of SIRT1 protein |
CTD |
PMID:23600725 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
increases expression |
ISO |
Clenbuterol results in increased expression of ACADM mRNA |
CTD |
PMID:17446185 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases activity |
ISO EXP |
[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose] Clenbuterol results in increased activity of ADRB2 protein |
CTD |
PMID:16007677 PMID:18552870 PMID:34601065 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
EXP |
Clenbuterol binds to and results in increased activity of ADRB3 protein |
CTD |
PMID:7815362 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein] |
CTD |
PMID:16339297 |
|
NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]] |
CTD |
PMID:15710352 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]] |
CTD |
PMID:15710352 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Esrra |
estrogen related receptor, alpha |
increases expression |
ISO |
Clenbuterol results in increased expression of ESRRA mRNA |
CTD |
PMID:17446185 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]; Clenbuterol inhibits the reaction [Reserpine results in increased expression of GAD1 mRNA]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]] |
CTD |
PMID:8774452 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Il10 |
interleukin 10 |
multiple interactions affects expression |
ISO EXP |
Clenbuterol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL10 protein] Clenbuterol affects the expression of IL10 protein |
CTD |
PMID:15021963 PMID:15502056 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
Clenbuterol results in increased expression of IL18 mRNA; Clenbuterol results in increased expression of IL18 protein |
CTD |
PMID:15178407 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:15021963 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:15021963 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Clenbuterol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] |
CTD |
PMID:15502056 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions increases stability increases activity |
ISO |
Alprenolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]; Metoprolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]; Propranolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein] Clenbuterol results in increased stability of ODC1 protein |
CTD |
PMID:10353628 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Clenbuterol results in increased expression of PDK4 mRNA |
CTD |
PMID:17446185 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO EXP |
Clenbuterol results in increased expression of PPARGC1A mRNA Propranolol inhibits the reaction [Clenbuterol results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:17446185 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein] |
CTD |
PMID:16339297 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Clenbuterol affects the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:15710352 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression |
ISO |
Clenbuterol results in increased expression of TFAM mRNA |
CTD |
PMID:17446185 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:15021963 PMID:15710352 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression |
ISO |
Clenbuterol results in increased expression of UCP1 protein |
CTD |
PMID:10465291 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases activity |
ISO |
clorprenaline results in increased activity of ADRB2 protein |
CTD |
PMID:34601065 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
clorprenaline inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Dicyclomine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases expression |
ISO EXP |
diethanolamine results in decreased expression of BAD mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
EXP ISO |
diethanolamine results in decreased expression of BAX mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Casp3 |
caspase 3 |
decreases expression increases activity |
ISO EXP |
diethanolamine results in decreased expression of CASP3 mRNA diethanolamine results in increased activity of CASP3 protein |
CTD |
PMID:16014740 PMID:18948303 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccnd2 |
cyclin D2 |
increases expression |
ISO EXP |
diethanolamine results in increased expression of CCND2 mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO EXP |
diethanolamine results in increased expression of CCNE1 mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO EXP |
diethanolamine results in decreased expression of CDKN1A mRNA |
CTD |
PMID:16014740 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
ISO EXP |
diethanolamine results in decreased expression of CDKN1B mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression |
ISO EXP |
diethanolamine results in increased expression of E2F1 mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[diethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
diethanolamine results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
ISO EXP |
diethanolamine results in decreased expression of TRP53 mRNA diethanolamine results in decreased expression of TP53 mRNA |
CTD |
PMID:16014740 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
esmolol results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
esmolol results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
esmolol results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
esmolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein] |
CTD |
PMID:16627864 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
esmolol results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
esmolol results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
esmolol results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
esmolol results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
esmolol results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
esmolol results in increased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ren |
renin |
multiple interactions |
ISO |
esmolol inhibits the reaction [Nitroprusside results in increased activity of REN protein] |
CTD |
PMID:2569849 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
esmolol results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
increases expression |
ISO |
esmolol results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
|
G |
Cat |
catalase |
affects response to substance |
ISO |
CAT protein affects the susceptibility to Etanidazole |
CTD |
PMID:2943713 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
increases expression |
ISO |
Ethambutol results in increased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
ISO |
Ethambutol results in decreased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in decreased activity of CAT protein |
CTD |
PMID:34118364 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
affects expression |
EXP |
Ethambutol affects the expression of CCL2 mRNA |
CTD |
PMID:25051504 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
affects expression |
EXP |
Ethambutol affects the expression of CCL5 protein |
CTD |
PMID:25051504 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
Ethambutol results in increased expression of and affects the localization of CTSD protein; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of and affects the localization of CTSD protein] |
CTD |
PMID:19063910 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Ethambutol results in decreased activity of CYP1A2 protein |
CTD |
PMID:24910189 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
Ethambutol results in decreased activity of CYP2C19 protein |
CTD |
PMID:24910189 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Ethambutol results in decreased activity of CYP2D6 protein |
CTD |
PMID:24910189 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
ISO EXP |
Ethambutol results in decreased activity of CYP2E1 protein [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:24910189 PMID:27919644 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] |
CTD |
PMID:27919644 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Gzmb |
granzyme B |
increases secretion |
ISO |
Ethambutol results in increased secretion of GZMB protein |
CTD |
PMID:27933861 |
|
NCBI chr15:30,343,361...30,346,792
Ensembl chr15:30,173,603...30,346,814
|
|
G |
Ifng |
interferon gamma |
increases secretion |
ISO |
Ethambutol results in increased secretion of IFNG protein |
CTD |
PMID:27933861 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
EXP |
Ethambutol results in decreased expression of IL10 protein |
CTD |
PMID:25051504 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13 |
interleukin 13 |
increases secretion |
ISO |
Ethambutol results in increased secretion of IL13 protein |
CTD |
PMID:27933861 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Ethambutol results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
Ethambutol results in decreased expression of IL1B mRNA |
CTD |
PMID:25051504 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
EXP |
Ethambutol results in decreased expression of IL6 protein |
CTD |
PMID:25051504 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
increases expression multiple interactions |
EXP |
Ethambutol results in increased expression of LAMP2 protein N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of LAMP2 protein] |
CTD |
PMID:19063910 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Lep |
leptin |
decreases expression |
EXP |
Ethambutol results in decreased expression of LEP protein |
CTD |
PMID:25051504 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
Ethambutol results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein |
CTD |
PMID:34118364 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Ethambutol results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Ethambutol results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Ethambutol results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
EXP |
[3-deazaadenosine co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form; [Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form; [Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form |
CTD |
PMID:8944747 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
EXP |
[3-deazaadenosine co-treated with Ethanolamine] results in decreased secretion of APOE protein; [Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOE protein; [Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOE protein |
CTD |
PMID:8944747 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Egf |
epidermal growth factor |
increases activity |
ISO |
Ethanolamine results in increased activity of EGF protein |
CTD |
PMID:15802876 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases activity |
ISO |
Ethanolamine results in increased activity of FGF1 protein |
CTD |
PMID:15802876 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Pnliprp2 |
pancreatic lipase related protein 2 |
increases metabolic processing |
EXP |
PNLIPRP2 protein results in increased metabolism of Ethanolamine |
CTD |
PMID:9822688 |
|
NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
ISO |
Indinavir results in decreased activity of ABCB11 protein Indinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:20829430 PMID:23956101 PMID:24014644 PMID:28437613 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
Indinavir inhibits the reaction [Celecoxib results in increased activity of ACHE protein]; Indinavir inhibits the reaction [Streptozocin results in increased activity of ACHE protein] |
CTD |
PMID:18343489 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression multiple interactions |
ISO |
Indinavir results in decreased expression of ADIPOQ protein diphenyleneiodonium inhibits the reaction [Indinavir results in decreased expression of ADIPOQ protein]; Indinavir inhibits the reaction [ADIPOQ protein modified form results in increased uptake of Deoxyglucose] Indinavir results in decreased expression of ADIPOQ mRNA; Indinavir results in decreased expression of ADIPOQ protein |
CTD |
PMID:15865214 PMID:17668557 PMID:29991592 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Aebp1 |
AE binding protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of AEBP1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr14:80,738,800...80,748,878
Ensembl chr14:80,738,892...80,748,877
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ALOX5AP mRNA |
CTD |
PMID:16931933 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
AGN 193109 inhibits the reaction [Indinavir promotes the reaction [Tretinoin results in increased expression of ALPL protein]]; Indinavir promotes the reaction [Tretinoin results in increased expression of ALPL protein] |
CTD |
PMID:10704935 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apob |
apolipoprotein B |
decreases secretion |
ISO |
Indinavir results in decreased secretion of APOB protein |
CTD |
PMID:32535746 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc3 |
apolipoprotein C3 |
decreases secretion decreases expression |
ISO |
Indinavir results in decreased secretion of APOC3 protein Indinavir results in decreased expression of APOC3 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Arpp21 |
cAMP regulated phosphoprotein 21 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ARPP21 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297
|
|
G |
Asic2 |
acid sensing ion channel subunit 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ASIC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:65,870,592...66,940,577
Ensembl chr10:65,870,594...66,940,424
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:11706060 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
C1r |
complement C1r |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C1R mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C3AR1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Indinavir results in increased expression of CCL2 protein diphenyleneiodonium inhibits the reaction [Indinavir results in increased expression of CCL2 protein] |
CTD |
PMID:17668557 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
ISO |
Indinavir results in increased expression of CCL3 protein |
CTD |
PMID:17668557 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CD36 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CIDEC mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CLCN3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr16:29,127,419...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Crp |
C-reactive protein |
decreases expression |
ISO |
Indinavir results in decreased expression of CRP protein |
CTD |
PMID:15622323 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DCN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Indinavir results in increased expression of DDIT3 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dusp3 |
dual specificity phosphatase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DUSP3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression |
ISO |
Indinavir results in increased expression of EIF2AK3 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ELOVL3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:244,997,287...245,001,115
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ETV6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FADS2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of FAIM mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:99,543,877...99,569,499
Ensembl chr 8:99,542,405...99,560,562
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
ISO |
Indinavir results in increased expression of FASN mRNA [Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA |
CTD |
PMID:11741158 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
G0s2 |
G0/G1switch 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of G0S2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
Ganc |
glucosidase, alpha; neutral C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of GANC mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 3:107,353,369...107,406,104
Ensembl chr 3:107,353,369...107,405,241
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of GUCY1B1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of HADH mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hcn1 |
hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of HCN1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:49,495,771...49,899,702
Ensembl chr 2:49,495,771...49,899,774
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
Indinavir results in increased expression of HSPA5 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Ikzf4 |
IKAROS family zinc finger 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of IKZF4 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:1,063,283...1,102,940
Ensembl chr 7:1,056,890...1,084,341
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
diphenyleneiodonium inhibits the reaction [Indinavir results in increased expression of IL6 protein] |
CTD |
PMID:17668557 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Klhl28 |
kelch-like family member 28 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of KLHL28 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 6:82,987,360...83,018,971
Ensembl chr 6:82,990,945...83,016,164
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of LAMC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr13:65,284,664...65,344,200
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lep |
leptin |
multiple interactions decreases expression |
ISO |
diphenyleneiodonium inhibits the reaction [Indinavir results in decreased expression of LEP protein] [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LEP mRNA |
CTD |
PMID:16931933 PMID:17668557 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lpl |
lipoprotein lipase |
decreases activity multiple interactions increases expression |
ISO |
Indinavir results in decreased activity of LPL protein [Stavudine co-treated with Lamivudine co-treated with Indinavir] affects the expression of LPL mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LPL mRNA Indinavir results in increased expression of LPL mRNA |
CTD |
PMID:11741158 PMID:11786383 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Me1 |
malic enzyme 1 |
multiple interactions |
ISO |
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA |
CTD |
PMID:11741158 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mgat4c |
MGAT4 family, member C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MGAT4C mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:36,709,564...37,485,810
Ensembl chr 7:37,260,321...37,474,571
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
Indinavir inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 mRNA]; Indinavir inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 protein]; Indinavir inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP2 protein] |
CTD |
PMID:14662518 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Indinavir inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]; Indinavir inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein]; Indinavir inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP9 protein] |
CTD |
PMID:14662518 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mrap |
melanocortin 2 receptor accessory protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of MRAP mRNA |
CTD |
PMID:16931933 |
|
NCBI chr11:29,991,974...30,003,024
Ensembl chr11:29,992,034...30,003,024
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases expression |
ISO |
Indinavir results in decreased expression of MTTP mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myod1 |
myogenic differentiation 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MYOD1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
Nap1l5 |
nucleosome assembly protein 1-like 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NAP1L5 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:88,022,670...88,024,988
Ensembl chr 4:88,022,569...88,024,654
|
|
G |
Noct |
nocturnin |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of NOCT mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NPPA mRNA |
CTD |
PMID:11706060 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
increases expression |
ISO |
Indinavir results in increased expression of NRF1 mRNA |
CTD |
PMID:17926646 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Nup210 |
nucleoporin 210 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NUP210 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:123,511,559...123,609,874
Ensembl chr 4:123,511,559...123,609,874
|
|
G |
Oaz3 |
ornithine decarboxylase antizyme 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of OAZ3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:182,073,212...182,076,147
Ensembl chr 2:182,073,215...182,082,399
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
increases expression |
ISO |
Indinavir results in increased expression of P4HB mRNA |
CTD |
PMID:32535746 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Pcdh15 |
protocadherin related 15 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PCDH15 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PFKFB3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
|
|
G |
Phf6 |
PHD finger protein 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PHF6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr X:132,656,658...132,699,720
Ensembl chr X:132,656,672...132,699,127
|
|
G |
Pidd1 |
p53-induced death domain protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIDD1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:196,536,815...196,542,808
Ensembl chr 1:196,536,834...196,542,699
|
|
G |
Piwil2 |
piwi-like RNA-mediated gene silencing 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIWIL2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr15:45,431,402...45,498,034
Ensembl chr15:45,431,703...45,497,702
|
|
G |
Porcn |
porcupine O-acyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PPN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr X:14,285,864...14,298,481
Ensembl chr X:14,285,871...14,298,481
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of POU5F1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
Indinavir results in decreased expression of PPARG mRNA |
CTD |
PMID:17926646 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prdm1 |
PR/SET domain 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PRDM1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488
|
|
G |
Reep6 |
receptor accessory protein 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of REEP6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597
|
|
G |
RGD1562378 |
histone H4 variant H4-v.1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of H4C9 mRNA |
CTD |
PMID:16931933 |
|
|
|
G |
Rnf151 |
ring finger protein 151 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of RNF151 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:13,742,682...13,747,192
Ensembl chr10:13,742,682...13,745,000
|
|
G |
Rpain |
RPA interacting protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of RPAIN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:55,692,410...55,699,910
Ensembl chr10:55,692,417...55,699,933
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of S100A8 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
Slc25a19 |
solute carrier family 25 member 19 |
multiple interactions |
ISO |
SLC25A19 protein affects the susceptibility to [Stavudine co-treated with Lamivudine co-treated with Indinavir]; SLC25A19 protein affects the susceptibility to [Zidovudine co-treated with Lamivudine co-treated with Indinavir] |
CTD |
PMID:15951836 |
|
NCBI chr10:100,853,554...100,867,517
Ensembl chr10:100,847,168...100,867,447
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
[Indinavir results in decreased activity of SLC2A4 protein] inhibits the reaction [resveratrol results in increased uptake of Deoxyglucose] |
CTD |
PMID:18601907 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Spink5 |
serine peptidase inhibitor, Kazal type 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of SPINK5 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr18:36,264,452...36,333,143
Ensembl chr18:36,264,452...36,332,185
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
decreases expression |
ISO |
Indinavir results in decreased expression of TFAP2A mRNA |
CTD |
PMID:17926646 |
|
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TIMP2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Indinavir inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:15388451 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trim42 |
tripartite motif-containing 42 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TRIM42 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:97,902,349...97,923,268
Ensembl chr 8:97,902,353...97,923,268
|
|
G |
Ucp1 |
uncoupling protein 1 |
decreases expression |
ISO |
Indinavir results in decreased expression of UCP1 mRNA |
CTD |
PMID:17926646 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Wnt10a |
Wnt family member 10A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of WNT10A mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 9:76,349,931...76,362,400
Ensembl chr 9:76,349,931...76,362,400
|
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
affects expression |
ISO |
Levobunolol affects the expression of HLA-DMB mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
|
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of BIRC3 protein] |
CTD |
PMID:25125499 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein] |
CTD |
PMID:25125499 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions increases expression |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of CFLAR mRNA] lysophosphatidylethanolamine analog results in increased expression of CFLAR protein Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein] lysophosphatidylethanolamine analog results in increased expression of CFLAR mRNA; lysophosphatidylethanolamine analog results in increased expression of CFLAR protein |
CTD |
PMID:25125499 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[lysophosphatidylethanolamine analog co-treated with cobaltous chloride] results in increased phosphorylation of GSK3B protein |
CTD |
PMID:25125499 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions increases expression |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of and results in increased degradation of MCL1 protein] lysophosphatidylethanolamine analog results in increased expression of MCL1 protein lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein] |
CTD |
PMID:25125499 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of lysophosphatidylethanolamine; [NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of lysophosphatidylethanolamine analog |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in increased activity of PARP1 protein] |
CTD |
PMID:25125499 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of lysophosphatidylethanolamine |
CTD |
PMID:30258081 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases expression increases activity affects expression increases phosphorylation multiple interactions |
ISO |
Metaproterenol results in decreased expression of ADRB2 protein Metaproterenol results in increased activity of ADRB2 protein Metaproterenol affects the expression of ADRB2 mRNA Metaproterenol results in increased phosphorylation of ADRB2 protein [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Metaproterenol binds to and results in increased activity of ADRB2 protein |
CTD |
PMID:16980553 PMID:24705868 PMID:34601065 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Metaproterenol results in increased expression of BAX protein |
CTD |
PMID:15052282 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
increases expression |
EXP |
Metaproterenol results in increased expression of BCAT1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Metaproterenol results in decreased expression of BCL2 protein |
CTD |
PMID:15052282 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bnip1 |
BCL2 interacting protein 1 |
increases expression |
ISO |
Metaproterenol results in increased expression of BNIP1 protein |
CTD |
PMID:15052282 |
|
NCBI chr10:16,386,876...16,399,124
Ensembl chr10:16,386,841...16,399,157
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Metaproterenol results in increased expression of CLU protein |
CTD |
PMID:15052282 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
EXP |
Metaproterenol results in increased expression of FABP3 protein |
CTD |
PMID:22878004 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression |
EXP |
Metaproterenol results in increased expression of FHL1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Metaproterenol results in decreased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Metaproterenol results in decreased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
increases expression |
EXP |
Metaproterenol results in increased expression of LMCD1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Metaproterenol results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Metaproterenol results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rnd1 |
Rho family GTPase 1 |
increases expression |
EXP |
Metaproterenol results in increased expression of RND1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
EXP |
Metaproterenol results in increased expression of SERPINE1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Metaproterenol results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
EXP |
Metaproterenol results in increased expression of SPP1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
EXP |
Metaproterenol results in increased expression of TGFB2 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
EXP |
Metaproterenol results in increased expression of TIMP1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnni3 |
troponin I3, cardiac type |
increases expression |
EXP |
Metaproterenol results in increased expression of TNNI3 protein |
CTD |
PMID:22878004 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
increases expression |
EXP |
Metaproterenol results in increased expression of TNNT2 protein |
CTD |
PMID:22878004 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Metipranolol inhibits the reaction [Zinc results in increased expression of BCL2 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in increased expression of BCL2 protein] |
CTD |
PMID:16799065 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Metipranolol inhibits the reaction [Zinc results in increased cleavage of CASP3 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP3 protein] |
CTD |
PMID:16799065 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Grk1 |
G protein-coupled receptor kinase 1 |
multiple interactions |
EXP |
Metipranolol inhibits the reaction [Zinc results in decreased expression of GRK1 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in decreased expression of GRK1 protein] |
CTD |
PMID:16799065 |
|
NCBI chr16:76,122,501...76,135,792
Ensembl chr16:76,123,842...76,135,792
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Metipranolol inhibits the reaction [Zinc results in decreased expression of PARP1 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in decreased expression of PARP1 protein] |
CTD |
PMID:16799065 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
|
G |
Ace |
angiotensin I converting enzyme |
affects response to substance |
ISO |
ACE gene polymorphism affects the susceptibility to Metoprolol |
CTD |
PMID:20819590 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
multiple interactions |
ISO |
[ADRB1 gene polymorphism co-treated with ADRA2C gene polymorphism] affects the susceptibility to Metoprolol |
CTD |
PMID:17496726 |
|
NCBI chr14:75,471,143...75,472,846
Ensembl chr14:75,471,143...75,472,846
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases activity affects binding multiple interactions increases expression decreases methylation affects response to substance |
ISO EXP |
Metoprolol results in decreased activity of ADRB1 protein Metoprolol binds to ADRB1 protein [ADRB1 gene polymorphism co-treated with ADRA2C gene polymorphism] affects the susceptibility to Metoprolol; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 gene polymorphism affects the susceptibility to [Dobutamine co-treated with Metoprolol]; Metoprolol binds to and results in decreased activity of ADRB1 protein; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [cyanopindolol binds to ADRB1 protein] Metoprolol results in increased expression of ADRB1 mRNA; Metoprolol results in increased expression of ADRB1 protein Metoprolol results in decreased methylation of ADRB1 promoter Metoprolol binds to and results in increased activity of ADRB1 protein; Metoprolol inhibits the reaction [Isoproterenol results in decreased expression of ADRB1 mRNA]; Metoprolol inhibits the reaction [Streptozocin results in decreased expression of ADRB1 protein] ADRB1 gene affects the susceptibility to Metoprolol; ADRB1 gene polymorphism affects the susceptibility to Metoprolol; ADRB1 protein polymorphism affects the susceptibility to Metoprolol |
CTD |
PMID:1312942 PMID:1389726 PMID:9593075 PMID:10372227 PMID:11562432 PMID:12844134 PMID:14730417 PMID:15060759 PMID:15864115 PMID:17200720 PMID:17496726 PMID:18703049 PMID:19094446 PMID:20590644 PMID:20675662 PMID:20821015 PMID:21311897 PMID:22165287 PMID:22192668 More...
|
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects binding multiple interactions increases expression affects response to substance |
EXP ISO |
Metoprolol binds to ADRB2 protein [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Metoprolol binds to and results in decreased activity of ADRB2 protein; Metoprolol inhibits the reaction [cyanopindolol binds to ADRB2 protein] Metoprolol promotes the reaction [Streptozocin results in increased expression of ADRB2 protein] Metoprolol results in increased expression of ADRB2 protein ADRB2 gene polymorphism affects the susceptibility to Metoprolol Metoprolol results in increased expression of ADRB2 mRNA |
CTD |
PMID:9593075 PMID:14730417 PMID:17671401 PMID:17925438 PMID:18703049 PMID:20675662 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions increases expression |
EXP ISO |
Metoprolol promotes the reaction [Streptozocin results in increased expression of ADRB3 protein] Metoprolol inhibits the reaction [cyanopindolol binds to ADRB3 protein] Metoprolol results in increased expression of ADRB3 protein |
CTD |
PMID:14730417 PMID:18703049 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
EXP |
Metoprolol results in increased phosphorylation of AKT1 protein |
CTD |
PMID:18703049 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
affects response to substance |
ISO |
ARRB2 protein affects the susceptibility to Metoprolol |
CTD |
PMID:22888001 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
EXP |
Metoprolol results in increased expression of ATP2A2 mRNA |
CTD |
PMID:16162791 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Isoproterenol results in increased expression of BCL2L1 protein] |
CTD |
PMID:12738230 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
Metoprolol results in increased cleavage of CASP3 protein |
CTD |
PMID:19106745 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
Metoprolol results in increased cleavage of CASP9 protein |
CTD |
PMID:19106745 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP ISO |
Metoprolol results in increased expression of CCN2 mRNA |
CTD |
PMID:22888001 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO EXP |
Metoprolol results in increased expression of COL1A1 mRNA |
CTD |
PMID:22888001 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression |
ISO |
Metoprolol results in increased expression of COL3A1 mRNA |
CTD |
PMID:30809271 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Metoprolol results in increased expression of CPT1A protein |
CTD |
PMID:19233164 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
multiple interactions decreases expression |
EXP |
Metoprolol inhibits the reaction [[[PPARGC1A protein results in increased expression of MEF2A mRNA] co-treated with [PPARGC1A protein results in increased expression of PPARA mRNA]] results in increased expression of CPT1B protein]; Metoprolol inhibits the reaction [MEF2A protein binds to CPT1B promoter]; Metoprolol inhibits the reaction [PPARGC1A protein binds to CPT1B promoter] Metoprolol results in decreased expression of CPT1B protein |
CTD |
PMID:19233164 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cyb5a |
cytochrome b5 type A |
affects metabolic processing |
ISO |
CYB5A affects the metabolism of Metoprolol |
CTD |
PMID:20430864 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance increases metabolic processing multiple interactions affects metabolic processing |
ISO |
CYP2D6 gene affects the susceptibility to Metoprolol; CYP2D6 gene polymorphism affects the susceptibility to Metoprolol CYP2D6 protein results in increased metabolism of Metoprolol [Paroxetine results in decreased activity of CYP2D6 protein] which results in decreased degradation of Metoprolol; [Paroxetine results in decreased activity of CYP2D6 protein] which results in increased susceptibility to Metoprolol; [Terbinafine results in decreased activity of CYP2D6 protein] inhibits the reaction [CYP2D6 protein results in increased metabolism of Metoprolol]; CYP2D6 gene polymorphism affects the reaction [Amiodarone results in increased abundance of Metoprolol]; Hydroxychloroquine inhibits the reaction [CYP2D6 protein results in increased metabolism of Metoprolol]; YM 758 inhibits the reaction [CYP2D6 protein results in increased metabolism of Metoprolol] CYP2D6 protein affects the metabolism of Metoprolol; CYP2D6 protein polymorphism affects the metabolism of Metoprolol |
CTD |
PMID:10470702 PMID:10848718 PMID:11823760 PMID:12172215 PMID:12464242 PMID:15286053 PMID:15327588 PMID:15541258 PMID:18648788 PMID:18784654 PMID:18979093 PMID:19094446 PMID:19230594 PMID:24894748 More...
|
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases hydroxylation |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Metoprolol] |
CTD |
PMID:30087611 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
decreases expression |
ISO |
Metoprolol results in decreased expression of ECE1 mRNA |
CTD |
PMID:9607404 |
|
NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Norepinephrine results in increased expression of EDN1 mRNA] |
CTD |
PMID:11435416 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
Metoprolol promotes the reaction [FKBP1B protein binds to RYR2 protein] |
CTD |
PMID:12743001 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo3 |
forkhead box O3 |
decreases expression |
EXP |
Metoprolol results in decreased expression of FOXO3 protein |
CTD |
PMID:18703049 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Norepinephrine results in increased activity of G6PD protein] |
CTD |
PMID:1378361 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gata4 |
GATA binding protein 4 |
decreases phosphorylation |
EXP |
Metoprolol results in decreased phosphorylation of GATA4 protein |
CTD |
PMID:21472269 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression affects localization multiple interactions |
EXP |
Metoprolol results in increased expression of GJA1 protein Metoprolol affects the localization of GJA1 protein [Isoproterenol co-treated with Metoprolol] results in increased expression of GJA1 protein |
CTD |
PMID:17445419 PMID:20215810 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Grk4 |
G protein-coupled receptor kinase 4 |
affects response to substance |
ISO |
GRK4 gene SNP affects the susceptibility to Metoprolol |
CTD |
PMID:19119263 |
|
NCBI chr14:75,998,554...76,080,808
Ensembl chr14:76,006,218...76,080,693
|
|
G |
Grk5 |
G protein-coupled receptor kinase 5 |
affects response to substance |
ISO |
GRK5 protein affects the susceptibility to Metoprolol |
CTD |
PMID:22888001 |
|
NCBI chr 1:260,028,269...260,223,699
Ensembl chr 1:260,028,242...260,218,701
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; Metoprolol inhibits the reaction [Xamoterol results in increased expression of HMOX1 protein] |
CTD |
PMID:15179140 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression increases secretion |
ISO |
Metoprolol results in increased expression of IL1A mRNA Metoprolol results in increased secretion of IL1A protein |
CTD |
PMID:17467819 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA] |
CTD |
PMID:11406463 PMID:12619890 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jph2 |
junctophilin 2 |
increases expression |
ISO |
Metoprolol results in increased expression of JPH2 protein |
CTD |
PMID:22375019 |
|
NCBI chr 3:151,994,768...152,058,941
Ensembl chr 3:151,994,778...152,058,904
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Metoprolol results in decreased activity of [KCNH2 protein binds to KCNH2 protein] Metoprolol results in decreased activity of KCNH2 protein |
CTD |
PMID:15679475 PMID:16314852 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [[[PPARGC1A protein results in increased expression of MEF2A mRNA] co-treated with [PPARGC1A protein results in increased expression of PPARA mRNA]] results in increased expression of CPT1B protein]; Metoprolol inhibits the reaction [MEF2A protein binds to CPT1B promoter] |
CTD |
PMID:19233164 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mir190 |
microRNA 190 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression decreases secretion multiple interactions |
ISO EXP |
Metoprolol results in decreased expression of MMP2 mRNA; Metoprolol results in decreased expression of MMP2 protein Metoprolol results in decreased secretion of MMP2 protein Metoprolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA] |
CTD |
PMID:15326086 PMID:20424515 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression decreases secretion |
ISO |
Metoprolol results in decreased expression of MMP9 mRNA; Metoprolol results in decreased expression of MMP9 protein Metoprolol results in decreased secretion of MMP9 protein |
CTD |
PMID:20424515 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
Metoprolol results in decreased expression of MYC protein |
CTD |
PMID:21472269 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Metoprolol promotes the reaction [Phenylephrine results in increased expression of MYH7 mRNA] |
CTD |
PMID:17592507 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
increases phosphorylation |
EXP |
Metoprolol results in increased phosphorylation of NFATC4 protein |
CTD |
PMID:21472269 |
|
NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [[Ramipril co-treated with Sodium Chloride deficiency] results in increased expression of NOS1 protein]; Metoprolol inhibits the reaction [Ramipril promotes the reaction [Sodium Chloride deficiency results in increased expression of NOS1 mRNA]]; Metoprolol inhibits the reaction [Sodium Chloride deficiency results in increased expression of NOS1 mRNA] |
CTD |
PMID:11832429 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Streptozocin results in increased expression of NOS2 protein] |
CTD |
PMID:18703049 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases expression |
EXP |
Metoprolol results in decreased expression of NOS3 protein |
CTD |
PMID:18703049 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions decreases expression |
EXP |
Metoprolol promotes the reaction [Phenylephrine results in increased expression of NPPA mRNA] Metoprolol results in decreased expression of NPPA mRNA |
CTD |
PMID:17592507 PMID:20353484 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
EXP |
Metoprolol results in decreased expression of NPPB mRNA; Metoprolol results in decreased expression of NPPB protein |
CTD |
PMID:11181074 PMID:20353484 PMID:30310171 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases metabolic processing |
ISO |
NR1I3 gene mutant form results in decreased metabolism of Metoprolol |
CTD |
PMID:27434302 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein] |
CTD |
PMID:10353628 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Isoproterenol results in increased expression of PENK mRNA] |
CTD |
PMID:1363325 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [[[PPARGC1A protein results in increased expression of MEF2A mRNA] co-treated with [PPARGC1A protein results in increased expression of PPARA mRNA]] results in increased expression of CPT1B protein] |
CTD |
PMID:19233164 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [[[PPARGC1A protein results in increased expression of MEF2A mRNA] co-treated with [PPARGC1A protein results in increased expression of PPARA mRNA]] results in increased expression of CPT1B protein]; Metoprolol inhibits the reaction [PPARGC1A protein binds to CPT1B promoter]; Metoprolol promotes the reaction [USF2 protein binds to PPARGC1A protein] |
CTD |
PMID:19233164 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
decreases expression |
EXP |
Metoprolol results in decreased expression of PPP3CA protein |
CTD |
PMID:30310171 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Prdx3 |
peroxiredoxin 3 |
increases expression |
EXP |
Metoprolol results in increased expression of PRDX3 protein |
CTD |
PMID:30310171 |
|
NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression decreases expression |
EXP ISO |
Metoprolol inhibits the reaction [Isoflurane results in increased expression of PTGS2 mRNA]; Metoprolol inhibits the reaction [Oxygen deficiency results in increased expression of PTGS2 mRNA] Metoprolol results in increased expression of PTGS2 mRNA Metoprolol results in decreased expression of PTGS2 mRNA; Metoprolol results in decreased expression of PTGS2 protein |
CTD |
PMID:17467819 PMID:20424515 PMID:21615343 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ren |
renin |
decreases expression |
ISO EXP |
Metoprolol results in decreased expression of REN protein Metoprolol results in decreased expression of REN mRNA |
CTD |
PMID:2454358 PMID:8203557 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases expression |
EXP |
Metoprolol results in increased expression of RPS6KB1 mRNA |
CTD |
PMID:28099878 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions increases activity |
ISO |
Metoprolol promotes the reaction [FKBP1B protein binds to RYR2 protein] Metoprolol results in increased activity of RYR2 protein |
CTD |
PMID:12743001 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
Sgcd |
sarcoglycan, delta |
affects response to substance |
ISO |
SGCD affects the susceptibility to Metoprolol |
CTD |
PMID:20675662 |
|
NCBI chr10:31,346,480...32,328,364
Ensembl chr10:31,280,511...31,724,840
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [SLC22A2 protein results in increased uptake of Metformin] |
CTD |
PMID:19740083 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Spn |
sialophorin |
decreases response to substance |
ISO |
SPN protein results in decreased susceptibility to Metoprolol |
CTD |
PMID:18711009 |
|
NCBI chr 1:181,746,937...181,759,564
Ensembl chr 1:181,746,429...181,759,628
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Metoprolol results in increased expression of TGFB1 mRNA |
CTD |
PMID:22888001 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression |
EXP |
Metoprolol results in decreased expression of THBS1 mRNA |
CTD |
PMID:20353484 |
|
NCBI chr 3:105,056,286...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Thbs4 |
thrombospondin 4 |
decreases expression |
EXP |
Metoprolol results in decreased expression of THBS4 mRNA |
CTD |
PMID:20353484 |
|
NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA] |
CTD |
PMID:15326086 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]] |
CTD |
PMID:15081246 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Usf2 |
upstream transcription factor 2, c-fos interacting |
multiple interactions increases expression |
EXP |
Metoprolol promotes the reaction [USF2 protein binds to PPARGC1A protein] Metoprolol results in increased expression of USF2 protein |
CTD |
PMID:19233164 |
|
NCBI chr 1:86,174,703...86,185,942
Ensembl chr 1:86,174,703...86,185,617
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Metoprolol results in decreased expression of VEGFA mRNA; Metoprolol results in decreased expression of VEGFA protein |
CTD |
PMID:20424515 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Deanol inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18324785 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein |
CTD |
PMID:21195056 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Asah2 |
N-acylsphingosine amidohydrolase 2 |
multiple interactions |
ISO |
N,N-dimethylsphingosine inhibits the reaction [ASAH2 protein results in increased expression of BCL2 protein] |
CTD |
PMID:15498114 |
|
NCBI chr 1:229,865,662...229,973,253
Ensembl chr 1:229,865,662...229,939,162
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
N,N-dimethylsphingosine inhibits the reaction [ASAH2 protein results in increased expression of BCL2 protein] |
CTD |
PMID:15498114 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
N,N-dimethylsphingosine inhibits the reaction [C5 protein results in increased activity of RELA protein] |
CTD |
PMID:19284563 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:21195056 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
N,N-dimethylsphingosine inhibits the reaction [Glucose results in increased expression of FN1 protein] |
CTD |
PMID:21998146 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
[Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein |
CTD |
PMID:21195056 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of PARP1 protein |
CTD |
PMID:21195056 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
N,N-dimethylsphingosine inhibits the reaction [C5 protein results in increased activity of RELA protein] |
CTD |
PMID:19284563 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sphk1 |
sphingosine kinase 1 |
decreases activity decreases expression multiple interactions |
ISO EXP |
N,N-dimethylsphingosine results in decreased activity of SPHK1 protein N,N-dimethylsphingosine results in decreased expression of SPHK1 protein N,N-dimethylsphingosine inhibits the reaction [Glucose results in increased activity of SPHK1 protein] |
CTD |
PMID:17065523 PMID:19284563 PMID:21195056 PMID:21998146 |
|
NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport |
ISO |
ABCB1 protein results in increased transport of N-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine |
CTD |
PMID:21436125 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
N-acetylsphingosine results in increased expression of ABCB1 |
CTD |
PMID:11573427 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
BCL2 protein inhibits the reaction [N-acetylsphingosine results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; N-acetylsphingosine inhibits the reaction [CAV1 protein results in increased phosphorylation of AKT1 protein]; N-acetylsphingosine results in decreased phosphorylation of and results in decreased activity of AKT1 protein N-acetylsphingosine results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:12640124 PMID:16215670 PMID:21821001 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases phosphorylation multiple interactions |
ISO |
N-acetylsphingosine results in decreased phosphorylation of BAD protein N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [N-acetylsphingosine results in decreased phosphorylation of BAD protein] |
CTD |
PMID:24420784 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
N-acetylsphingosine results in increased expression of BAX mRNA |
CTD |
PMID:24420784 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
BCL2 protein inhibits the reaction [N-acetylsphingosine results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; BCL2 protein inhibits the reaction [N-acetylsphingosine results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [N-acetylsphingosine results in increased degradation of PLCG1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [N-acetylsphingosine results in decreased expression of BCL2 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [N-acetylsphingosine results in decreased expression of BCL2 protein]; sphingosine 1-phosphate inhibits the reaction [N-acetylsphingosine results in decreased expression of BCL2 mRNA]; sphingosine 1-phosphate inhibits the reaction [N-acetylsphingosine results in decreased expression of BCL2 protein] N-acetylsphingosine results in decreased expression of BCL2 mRNA; N-acetylsphingosine results in decreased expression of BCL2 protein |
CTD |
PMID:9295281 PMID:16215670 PMID:24420784 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases degradation |
ISO |
LGALS3 inhibits the reaction [N-acetylsphingosine results in increased degradation of BCL2L1 protein] |
CTD |
PMID:21821001 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
BCL2 protein inhibits the reaction [N-acetylsphingosine results in increased cleavage of and results in increased activity of CASP3 protein]; N-acetylsphingosine results in increased cleavage of and results in increased activity of CASP3 protein N-acetylsphingosine results in increased activity of CASP3 protein |
CTD |
PMID:10919278 PMID:16215670 PMID:21259059 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
N-acetylsphingosine inhibits the reaction [CAV1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:12640124 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions decreases localization |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [N-acetylsphingosine results in decreased localization of CEBPB protein]; N-acetylsphingosine inhibits the reaction [oltipraz results in increased localization of CEBPB protein] |
CTD |
PMID:15319326 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases activity |
ISO |
N-acetylsphingosine results in increased activity of CFTR protein |
CTD |
PMID:15474513 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Clk1 |
CDC-like kinase 1 |
increases expression |
ISO |
N-acetylsphingosine results in increased expression of CLK1 mRNA |
CTD |
PMID:18270325 |
|
NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000
|
|
G |
Ctsd |
cathepsin D |
increases secretion |
EXP |
N-acetylsphingosine results in increased secretion of CTSD protein |
CTD |
PMID:15040013 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Dapk1 |
death associated protein kinase 1 |
increases activity |
ISO EXP |
N-acetylsphingosine results in increased activity of DAPK1 protein |
CTD |
PMID:17087515 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
increases activity |
EXP |
N-acetylsphingosine results in increased activity of DFFB protein |
CTD |
PMID:15040013 |
|
NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628
|
![JBrowse link]() | |